 | |
| Abbreviation | ALS TDI |
|---|---|
| Founded | 1999 |
| Founder |
|
| Type | non-profit biotech |
| 04-3462719 | |
| Location |
|
Key people |
|
| Affiliations | International Alliance of ALS/MND Associations |
| Website | als.net |
The ALS Therapy Development Institute (ALS TDI) is a non-profit biotechnology research organization focused on finding treatments for amyotrophic lateral sclerosis (ALS). With a staff including more than 30 scientists, it operates a research and development program centered on ALS. [1] [2]
ALS TDI was founded as the ALS Therapy Development Foundation (ALS TDF) in 1999 by James Heywood, Robert Bonazoli, and Melinda Marsh Heywood after James' brother, Stephen Heywood, was diagnosed with the disease. [3] Dr. Tennore Ramesh joined ALS-TDF when his sister in law was diagnosed with ALS and setup the research facility and served as Chief Scientific Officer from inception until 2003. The organization was initially funded through a donation from Stephen, as well as one from Alex and Brit d'Arbeloff. The Foundation's first therapy concept was to replace EAAT2 protein using gene therapy. [2] [4]
In 2004, the Foundation moved to a 16,000-square-foot (1,500 m2) location in Cambridge, Massachusetts with an in-house lab. ALS TDF constructed a biosafety level 2 lab in 2005, allowing for the expansion of "gene therapy and cell-based treatment pipelines." [2]
In 2005, the Foundation started the Tri-State Trek, an annual 270-mile bike ride from Boston, Massachusetts to Greenwich, Connecticut. [2] The Trek has since grown to include over 400 participants and has raised more than $7 million for research. [5] [6]
In 2006 the ALS patient Augie Nieto became chairman of the board. [2] The next year, James Heywood resigned as president but joined the board and Sean F. Scott, who ALS runs in his family, replaced him. [7] Scott worked with Augie Nieto as well as with the Muscular Dystrophy Association to bring together the two organizations in 2007. The collaboration allowed for MDA to match ALS TDI's annual budget for three years through Nieto's initiative, Augie's Quest, though the partnership continued after that, with MDA cumulatively providing over $36 million. [8] [9] The same year, the organization replaced the "Foundation" part of its name with "Institute". [2]
The Institute received a $1.1 million grant from the U.S. Department of Defense in 2008 and an additional $1.6 million grant in 2010. [2] [10]
Steven Perrin, previously only chief scientific officer, was appointed CEO in 2009 following the death of Sean Scott. [11] In 2011, the institute moved to a new 26,000-square-foot (2,400 m2) facility, also in Cambridge, allowing for the hiring of more scientists and a bigger lab. [2]
Two years later, in 2014, Augie's Quest officially transitioned from MDA to ALS TDI. [12] The same year, ALS TDI received over $3 million through the Ice Bucket Challenge. [1] In 2016, the Institute announced the ALS ONE partnership with Massachusetts General Hospital, Harvard Medical School, University of Massachusetts Medical School, and Compassionate Care ALS to find a treatment for ALS within four years. [13]
In 2018, ALS TDI was the original beneficiary of the ALS Pepper Challenge, where participants eat a chili pepper. [14] Various public figures, including Kelly Clarkson, Jimmy Kimmel, Shaquille O'Neal, Nancy O'Dell, Wolf Blitzer, the Miami Heat and Andy Cohen have participated in the challenge. [15] [16]
In February 2021, the ALS Therapy Development Institute moved to Watertown, MA. [17] The new location included a lab facility allowing preclinical, clinical and transitional research to happen in one place. [17]
In April 2021, Fernando Vieira, M.D., was appointed the chief executive officer of the ALS Therapy Development Institute by the board of directors. [18]
On February 22, 2023, the chairman of the board, Augie Nieto, passed from ALS.
The institute has raised and spent more than $100 million on research into effective treatments for ALS and practices open-source science. [19] After the discovery that the multiple sclerosis drug Gilenya might also be a treatment for ALS, the Institute enrolled 30 people in a Phase 2A clinical trial the drug in 2013, though it did not progress further. [20] [21] [22]
ALS TDI launched the Precision Medicine Program in partnership with Denali Therapeutics in 2013 "to identify subgroups of ALS, potential treatments for them using patient data, genomics and iPS cell technology". [23] By 2015, over 300 people had been registered and pre-screened in the program, significantly funded by money raised in the Ice Bucket Challenge. [24] [25] [26]
In 2018, the Institute entered Phase I clinical trials for AT-1501, a potential treatment for ALS and Alzheimer's [27] that blocks the activation of certain immune cells in order to protect nerves from ALS. [28] The development of the drug allows ALS TDI to be viewed as a successful drug development organization. [29] ALS TDI received funding from the ALS ONE partnership to develop the drug. [30]
In 2020 the Institute Published "Type I PRMT Inhibition Protects Against C9ORF72 Arginine-Rich Dipeptide Repeat Toxicity" in Frontiers in Pharmacology with a follow-up paper in 2021 called "Hypothesis and Theory: Roles of Arginine Methylation in C9orf72-Mediated ALS and FTD" in Frontiers in Cellular Neuroscience. [31]
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.
Muscular Dystrophy Association (MDA) is an American nonprofit organization dedicated to supporting people living with muscular dystrophy, ALS, and related neuromuscular diseases. Founded in 1950 by Paul Cohen, who lived with muscular dystrophy, MDA accelerates research, advances care, and works to empower families to live longer and more independent lives but is perhaps known for its working relationship with comedian, entertainer and actor Jerry Lewis, its national chairman of 55 years, number one volunteer and host of his annual telethon held each Labor Day weekend live. The organization's headquarters is in Chicago, Illinois.
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total.
James Heywood is an American MIT mechanical engineer who founded with his family the ALS Therapy Development Institute when his younger brother Stephen Heywood was diagnosed with amyotrophic lateral sclerosis (ALS) in December 1998. He is currently a director at AOBiome, as well as founder and CEO of PatientsLikeMe.
The ALS Association is an American nonprofit organization that funds global amyotrophic lateral sclerosis (ALS) research, provides care services and programs to people affected by ALS through its nationwide network of clinical care centers, and works with ALS advocates around the country for state and federal policies that serve people living with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Augustine L. Nieto II was the founder and chief executive of Life Fitness, as well as the chairman of Augie's Quest to Cure ALS, and the ALS Therapy Development Institute. He and his wife, Lynne, lived in Corona Del Mar, California, and had four children and eight grandchildren.
PatientsLikeMe (PLM) is an integrated community, health management, and real-world data platform. The platform currently has over 830,000 members who are dealing with more than 2,900 conditions, such as ALS, MS, and epilepsy. Data generated by patients themselves are collected and quantified with the goal of providing an environment for peer support and learning. These data capture the influences of different lifestyle choices, socio-demographics, conditions and treatments on a person's health.
Sean Forrester Scott was a self-educated disease activist and researcher, filmmaker, innovator, entrepreneur and until the time of his death, the president of the ALS Therapy Development Institute, the world's largest amyotrophic lateral sclerosis research center. Scott himself was diagnosed with ALS in 2008 at the age of 38.
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
Pelareorep is a proprietary isolate of the unmodified human reovirus being developed as a systemically administered immuno-oncological viral agent for the treatment of solid tumors and hematological malignancies. Pelareorep is an oncolytic virus, which means that it preferentially lyses cancer cells. Pelareorep also promotes an inflamed tumor phenotype through innate and adaptive immune responses. Preliminary clinical trials indicate that it may have anti-cancer effects across a variety of cancer types when administered alone and in combination with other cancer therapies.
Flexion Therapeutics, Inc. is an American biopharmaceutical company based in Burlington, Massachusetts that is focused on the discovery, development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the most common form of arthritis.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Sio Gene Therapies, Inc. was a clinical-stage pharmaceutical company that developed gene therapies to treat neurological disorders. The company was headquartered in New York City and was incorporated in Basel, Switzerland. The company was founded by former hedge fund analyst and 2024 Republican Party presidential primary candidate Vivek Ramaswamy in October 2014 as a wholly owned subsidiary of Roivant Sciences, which was itself founded in May 2014.
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
Cancer Breakthroughs 2020, also known as Cancer Moonshot 2020 is a coalition with the goal of finding vaccine-based immunotherapies against cancer. By pooling the resources of multinational pharmaceutical, biotechnology companies, academic centers and oncologists, it intends to create access to over 60 novel and approved agents under exploration in the war against cancer and is expected to enable rapid testing of novel immunotherapy combination protocols. The initiative is being managed by a consortium of companies called The National Immunotherapy Coalition.
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.
Research on amyotrophic lateral sclerosis (ALS) has focused on animal models of the disease, its mechanisms, ways to diagnose and track it, and treatments.
John B. Heywood is a British mechanical engineer known for his work on automotive engine research, for authoring a number of field-defining textbooks on the internal combustion engine, and as the director of the Sloan Automotive Lab at the Massachusetts Institute of Technology (MIT).
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
